Galectin Therapeutics (GALT) Preferred Stock Liabilities (2011 - 2026)

Galectin Therapeutics' Preferred Stock Liabilities history runs 16 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Preferred Stock Liabilities changed 0.0% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (changed 0.0% YoY), while the FY2025 annual figure was $1.7 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $1.7 million, roughly flat from $1.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $1.7 million in Q1 2022, with the low at $1.7 million in Q1 2022.
• The 5-year median for Preferred Stock Liabilities is $1.7 million (2022), against an average of $1.7 million.
• Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
• Galectin Therapeutics' Preferred Stock Liabilities stood at $1.7 million in 2022, then changed by 0.0% to $1.7 million in 2023, then changed by 0.0% to $1.7 million in 2024, then changed by 0.0% to $1.7 million in 2025, then changed by 0.0% to $1.7 million in 2026.
• Business Quant data shows GALT's Preferred Stock Liabilities at $1.7 million in Q1 2026, $1.7 million in Q4 2025, and $1.7 million in Q3 2025.